AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO

Just a few days after AbbVie went all in on a Covid-19 antibody, its partner has officially wrapped its IPO.

Listing on the Hong Kong Stock Exchange, Harbour BioMed has raised $221 million with help from nine cornerstone investors: BlackRock Fund, HBM Healthcare, Hillhouse Capital, Hudson Bay Capital, Octagon Investments, Anlan Fund, Legend Capital, OrbiMed and 3W Capital.